Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure

被引:25
作者
Pathak, Ranjan [1 ]
Pharaon, Rebecca R. [1 ]
Mohanty, Atish [1 ]
Villaflor, Victoria M. [1 ]
Salgia, Ravi [1 ]
Massarelli, Erminia [1 ]
机构
[1] City Hope Natl Med Ctr, Dept Med Oncol & Therapeut Res, Duarte, CA 91010 USA
关键词
lung cancer; PD-1; PD-L1; immunotherapy; immune checkpoint inhibitors; acquired resistance; T-CELL DYSFUNCTION; PD-1; BLOCKADE; TUMOR MICROENVIRONMENT; CHECKPOINT BLOCKADE; UP-REGULATION; IMMUNOTHERAPY; THERAPY; EXPRESSION; LANDSCAPE; EVOLUTION;
D O I
10.3390/cancers12123851
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Acquired resistance to immunotherapy is an emerging issue, especially as the indications for immunotherapy expand to many different solid tumor malignancies. This review attempts to summarize the mechanisms and clinical outcomes of acquired resistance in non-small-cell lung cancers and explores future directions for research to understand and address this important question. Immunotherapy is now the preferred treatment for most lung cancer patients. It is used to treat unresectable stage III non-small-cell lung cancer and is the first-line therapy for non-oncogene-driven advanced/metastatic non-small-cell lung cancer patients (either alone or in combination with chemotherapy). Unfortunately, most patients that respond initially to immunotherapy develop resistance over time, thus limiting the durability of immunotherapy. A better understanding of the mechanisms of acquired resistance is urgently needed to expand the benefit of immunotherapy in lung cancer patients. This review aims to summarize the mechanisms and clinical outcomes of acquired resistance of anti-PD-1/PD-L1 therapies in non-small-cell lung cancer patients.
引用
收藏
页码:1 / 13
页数:13
相关论文
共 75 条
[1]   IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer [J].
Abiko, K. ;
Matsumura, N. ;
Hamanishi, J. ;
Horikawa, N. ;
Murakami, R. ;
Yamaguchi, K. ;
Yoshioka, Y. ;
Baba, T. ;
Konishi, I. ;
Mandai, M. .
BRITISH JOURNAL OF CANCER, 2015, 112 (09) :1501-1509
[2]   Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer [J].
Anagnostou, Valsamo ;
Smith, Kellie N. ;
Forde, Patrick M. ;
Niknafs, Noushin ;
Bhattacharya, Rohit ;
White, James ;
Zhang, Theresa ;
Adleff, Vilmos ;
Phallen, Jillian ;
Wali, Neha ;
Hruban, Carolyn ;
Guthrie, Violeta B. ;
Rodgers, Kristen ;
Naidoo, Jarushka ;
Kang, Hyunseok ;
Sharfman, William ;
Georgiades, Christos ;
Verde, Franco ;
Illei, Peter ;
Li, Qing Kay ;
Gabrielson, Edward ;
Brock, Malcolm V. ;
Zahnow, Cynthia A. ;
Baylin, Stephen B. ;
Scharpf, Robert B. ;
Brahmer, Julie R. ;
Karchin, Rachel ;
Pardoll, Drew M. ;
Velculescu, Victor E. .
CANCER DISCOVERY, 2017, 7 (03) :264-276
[3]   Concurrent Mutations in STK11 and KEAP1 is Associated with Resistance to PD-(L) 1 Blockade in Patients with NSCLC Despite High TMB [J].
Arbour, K. ;
Shen, R. ;
Plodkowski, A. ;
Rizvi, H. ;
Ni, A. ;
Long, N. ;
Halpenny, D. ;
Sanchez-Vega, F. ;
Rudin, C. ;
Riely, G. ;
Hellmann, M. .
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) :S424-S424
[4]   Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer [J].
Arbour, Kathryn C. ;
Mezquita, Laura ;
Long, Niamh ;
Rizvi, Hira ;
Auclin, Edouard ;
Ni, Andy ;
Martinez-Bernal, Gala ;
Ferrara, Roberto ;
Lai, W. Victoria ;
Hendriks, Lizza E. L. ;
Sabari, Joshua K. ;
Caramella, Caroline ;
Plodkowski, Andrew J. ;
Halpenny, Darragh ;
Chaft, Jamie E. ;
Planchard, David ;
Riely, Gregory J. ;
Besse, Benjamin ;
Hellmann, Matthew D. .
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (28) :2872-+
[5]   Myeloid-derived suppressor cell impact on endogenous and adoptively transferred T cells [J].
Arina, Ainhoa ;
Bronte, Vincenzo .
CURRENT OPINION IN IMMUNOLOGY, 2015, 33 :120-125
[6]   In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy [J].
Arlauckas, Sean P. ;
Garris, Christopher S. ;
Kohler, Rainer H. ;
Kitaoka, Maya ;
Cuccarese, Michael F. ;
Yang, Katherine S. ;
Miller, Miles A. ;
Carlson, Jonathan C. ;
Freeman, Gordon J. ;
Anthony, Robert M. ;
Weissleder, Ralph ;
Pittet, Mikael J. .
SCIENCE TRANSLATIONAL MEDICINE, 2017, 9 (389)
[7]   Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma [J].
Auslander, Noam ;
Zhang, Gao ;
Lee, Joo Sang ;
Frederick, Dennie T. ;
Miao, Benchun ;
Moll, Tabea ;
Tian, Tian ;
Wei, Zhi ;
Madan, Sanna ;
Sullivan, Ryan J. ;
Boland, Genevieve ;
Flaherty, Keith ;
Herlyn, Meenhard ;
Ruppin, Eytan .
NATURE MEDICINE, 2018, 24 (10) :1545-+
[8]   Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses [J].
Beavis, Paul A. ;
Milenkovski, Nicole ;
Henderson, Melissa A. ;
John, Liza B. ;
Allard, Bertrand ;
Loi, Sherene ;
Kershaw, Michael H. ;
Stagg, John ;
Darcy, Phillip K. .
CANCER IMMUNOLOGY RESEARCH, 2015, 3 (05) :506-517
[9]   89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer [J].
Bensch, Frederike ;
van der Veen, Elly L. ;
Lub-de Hooge, Marjolijn N. ;
Jorritsma-Smit, Annelies ;
Boellaard, Ronald ;
Kok, Iris C. ;
Oosting, Sjoukje F. ;
Schroder, Carolina P. ;
Hiltermann, T. Jeroen N. ;
van der Wekken, Anthonie J. ;
Groen, Harry J. M. ;
Kwee, Thomas C. ;
Elias, Sjoerd G. ;
Gietema, Jourik A. ;
Bohorquez, Sandra Sanabria ;
de Crespigny, Alex ;
Williams, Simon-Peter ;
Mancao, Christoph ;
Brouwers, Adrienne H. ;
Fine, Bernard M. ;
de Vries, Elisabeth G. E. .
NATURE MEDICINE, 2018, 24 (12) :1852-+
[10]   PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells [J].
Blank, C ;
Brown, I ;
Peterson, AC ;
Spiotto, M ;
Iwai, Y ;
Honjo, T ;
Gajewski, TF .
CANCER RESEARCH, 2004, 64 (03) :1140-1145